pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

The association between medication use for dyslipidemia and osteoporosis by subgroups

Patients characteristics OR (95% CI) ORadj (95% CI)
Gender Man Non dyslipidemia Reference Reference
Ezetimibe users 3.58 (1.58-8.12) 0.93 (0.40-2.16)a
All statin users 3.80 (3.64-3.97) 0.83 (0.79-0.88)a
Low intensity 4.92 (3.85-6.30) 0.89 (0.68-1.15)a
Moderate intensity 3.75 (3.58-3.93) 0.83 (0.79-0.88)a
High intensity 4.20 (3.70-4.77) 0.84 (0.73-0.96)a
Woman Non dyslipidemia Reference Reference
Ezetimibe users 4.53 (3.14-6.53) 1.25 (0.84-1.86)a
All statin users 4.63 (4.55-4.72) 0.99 (0.97-1.02)a
Low intensity 4.34 (3.85-4.88) 0.89 (0.78-1.01)a
Moderate intensity 4.65 (4.57-4.74) 0.99 (0.97-1.02)a
High intensity 4.40 (4.09-4.74) 0.89 (0.82-0.96)a
Age group < 65 years Non dyslipidemia Reference Reference
Ezetimibe users 4.17 (2.56-6.80) 0.83 (0.49-1.41)b
All statin users 4.35 (4.24-4.47) 0.99 (0.97-1.02)b
Low intensity 4.32 (3.60-5.20) 0.88 (0.72-1.07)b
Moderate intensity 4.41 (4.30-4.53) 0.85 (0.82-0.88)b
High intensity 3.37 (3.03-3.74) 0.84 (0.74-0.94)b
≥65 years Non dyslipidemia Reference Reference
Ezetimibe users 1.80 (1.16-2.79) 1.38 (0.84-2.26)b
All statin users 1.61 (1.58-1.65) 1.00 (0.97-1.03)b
Low intensity 1.41 (1.24-1.60) 0.92 (0.80-1.06)b
Moderate intensity 1.65 (1.61-1.68) 1.01 (0.98-1.04)b
High intensity 1.20 (1.11-1.30) 0.92 (0.84-0.99)b

ORadja; odds ratio adjusted by patients’ age, insurance type, diabetes mellitus, fracture, rheumatoid arthritis, thyroid disease, ovarian hypofunction, and hormone replacement therapy

ORadjb; odds ratio adjusted by gender, insurance type, diabetes mellitus, fracture, rheumatoid arthritis, thyroid disease, ovarian hypofunction, and hormone replacement therapy
Korean J Clin Pharm 2021;31:278-84 https://doi.org/10.24304/kjcp.2021.31.4.278
© 2021 Korean J Clin Pharm